neoplasms

PEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis.

Cancer-associated cachexia (CAC) is a multifactorial metabolic syndrome characterized by progressive skeletal muscle wasting. However, the molecular link between tumor metabolic stress and muscle degradation remains elusive. Here, we identify phosphatidylethanolamine-binding protein 4 (PEBP4) as a key regulator of muscle...

🗓️ 2026-06-04
📰 Publication: Cell Death & Disease
Read MorePEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis.

Exercise training prior to and during cancer in mice preserves muscle mass, reduces tumour weight and suppresses molecular mediators of cachexia.

We investigated the prophylactic effects of exercise before and during cancer cachexia (CC) using a model designed to mimic endurance and resistance (i.e., concurrent) adaptations. Male and female Balb/c mice were randomly assigned to exercise or control groups whereby exercise...

🗓️ 2026-06-04
📰 Publication: Journal Of Physiology-London
Read MoreExercise training prior to and during cancer in mice preserves muscle mass, reduces tumour weight and suppresses molecular mediators of cachexia.

Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.

PURPOSE

The adverse prognostic impact of cancer cachexia is well recognized. We aimed to evaluate the prognostic impact of weight loss during first-line platinum-based chemo(immuno)therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC).

METHODS

We retrospectively reviewed 187 of 346 ED-SCLC patients (54%)...

🗓️ 2026-06-02
📰 Publication: Supportive Care In Cancer
Read MorePrognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.

Novel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

BACKGROUND

Cancer cachexia is a debilitating syndrome marked by involuntary weight loss resulting from reduced food intake and intricate metabolic reprogramming. Despite its high prevalence, cancer cachexia remains undertreated, with a lack of effective and approved pharmacotherapies. Ghrelin has emerged as...

🗓️ 2026-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNovel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

Glial remodeling and neuroprotective effects of L-glutamine supplementation on the enteric nervous system in walker-256 tumor-bearing rats.

Cancer cachexia is characterized by systemic inflammation and severe metabolic imbalance, which may compromise the cellular components of the enteric nervous system (ENS). Oxidative stress associated with tumor growth can contribute to enteric neuropathy and gastrointestinal dysfunction. This study investigated...

🗓️ 2026-05-31
📰 Publication: Tissue & Cell
Read MoreGlial remodeling and neuroprotective effects of L-glutamine supplementation on the enteric nervous system in walker-256 tumor-bearing rats.

Eating-related distress in cancer cachexia: multicentre self-reported questionnaire study.

OBJECTIVES

The Asian Working Group for Cachexia (AWGC) updated the diagnostic criteria for cachexia, emphasising its multidimensional influence. We hypothesised that patients meeting the AWGC criteria would exhibit higher levels of eating-related distress (ERD) than those meeting the European Palliative Care...

🗓️ 2026-05-28
📰 Publication: Bmj Supportive & Palliative Care
Read MoreEating-related distress in cancer cachexia: multicentre self-reported questionnaire study.

Formation of Liver Metastases Is Accompanied by Accelerated Musculoskeletal Deficits in LLC Tumor Hosts.

Lung cancer is a leading cause of death worldwide and is often accompanied by declines in musculoskeletal health (i.e., cachexia). Despite affecting a majority of lung cancer patients, cachexia remains understudied and currently has no cure. We have previously demonstrated...

🗓️ 2026-05-27
📰 Publication: International Journal Of Molecular Sciences
Read MoreFormation of Liver Metastases Is Accompanied by Accelerated Musculoskeletal Deficits in LLC Tumor Hosts.

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

BACKGROUND

Cancer cachexia is associated with rapid body wasting and cardiac dysfunction. Bisoprolol (BIS) and megestrol acetate (MA) improve selected cachexia phenotypes in the Yoshida AH-130 model, but their combined effects are not defined. We tested reduced-dose combined treatment of BIS...

🗓️ 2026-05-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCombined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Liver-derived ceramides link metabolism to tissue wasting in cancer cachexia.

Cancer cachexia, characterized by weight loss, muscle wasting, and anorexia, complicates cancer treatment and adversely affects patient outcomes. Both tumor-derived and host inflammatory factors are implicated in aspects of cachexia. The search for circulating mediators of cancer cachexia has focused...

🗓️ 2026-05-15
📰 Publication: Journal Of Clinical Investigation
Read MoreLiver-derived ceramides link metabolism to tissue wasting in cancer cachexia.

Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model.

Cachexia is a metabolic wasting syndrome affecting many patients with cancer, with poor survival outcomes. Disturbed lipid metabolism is a hallmark of cachexia, and our previous work has identified increased levels of circulating ceramides, which are bioactive lipids with adverse...

🗓️ 2026-05-15
📰 Publication: Journal Of Clinical Investigation
Read MoreInhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model.

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

BACKGROUND

In a recent Phase 2 trial in patients with cancer cachexia, the anti-GDF-15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF-15 pathway may offer a viable...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

Differential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle and adipose tissue that is often resistant to nutritional support. The branched-chain amino acids (BCAA: leucine, isoleucine, and valine) stimulate protein synthesis, yet BCAA-targeted therapies have yielded...

🗓️ 2026-05-13
📰 Publication: American Journal Of Physiology-Regulatory Integrative And Comparative Physiology
Read MoreDifferential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

GDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

Metastasis and cancer-induced cachexia significantly reduce survivorship and quality of life for cancer patients. GDF10 (BMP3b) is a TGF-ß superfamily ligand with little knowledge of its role in cancer progression. Some studies have shown that GDF10 exerts tumor-suppressive effects in...

🗓️ 2026-05-11
Read MoreGDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

RAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

BACKGROUND

Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end-products (RAGE) is expressed by several cell types and sustains the inflammatory response in...

🗓️ 2026-05-09
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Growth differentiation factor-15 (GDF15), a stress-responsive cytokine of the transforming growth factor-β superfamily, is elevated in cancer cachexia, chemotherapy-induced nausea, and hyperemesis gravidarum, making it both a biomarker and a therapeutic target. Here, we developed high-affinity GDF15 binders using an...

🗓️ 2026-05-09
📰 Publication: Experimental And Molecular Medicine
Read MoreDe novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

FcRn function alone cannot account for elevated IgG clearance in the Lewis lung carcinoma model of cancer cachexia.

PURPOSE

The neonatal Fc receptor (FcRn) protects IgG-based monoclonal antibodies (mAbs) from catabolism by direct binding within endosomes and facilitates their recycling to extracellular spaces. Elevated clearance of immune checkpoint inhibitors (ICIs) and other IgG-based mAbs is often observed in patients...

🗓️ 2026-05-09
📰 Publication: International Immunopharmacology
Read MoreFcRn function alone cannot account for elevated IgG clearance in the Lewis lung carcinoma model of cancer cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!